TWI789644B - 抗－N3pGlu類澱粉β肽抗體及其用途 - Google Patents

抗－N3pGlu類澱粉β肽抗體及其用途 Download PDF

Info

Publication number
TWI789644B
TWI789644B TW109140166A TW109140166A TWI789644B TW I789644 B TWI789644 B TW I789644B TW 109140166 A TW109140166 A TW 109140166A TW 109140166 A TW109140166 A TW 109140166A TW I789644 B TWI789644 B TW I789644B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
amino acid
acid sequence
mammalian cell
Prior art date
Application number
TW109140166A
Other languages
English (en)
Chinese (zh)
Other versions
TW202120541A (zh
Inventor
拉諾 布萊德理 德瑪托斯
吉讓 盧
唐鷹
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202120541A publication Critical patent/TW202120541A/zh
Application granted granted Critical
Publication of TWI789644B publication Critical patent/TWI789644B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW109140166A 2017-04-20 2018-04-09 抗－N3pGlu類澱粉β肽抗體及其用途 TWI789644B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20
US62/487,550 2017-04-20

Publications (2)

Publication Number Publication Date
TW202120541A TW202120541A (zh) 2021-06-01
TWI789644B true TWI789644B (zh) 2023-01-11

Family

ID=62111232

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109140166A TWI789644B (zh) 2017-04-20 2018-04-09 抗－N3pGlu類澱粉β肽抗體及其用途
TW107112023A TWI705975B (zh) 2017-04-20 2018-04-09 抗－N3pGlu類澱粉β肽抗體及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107112023A TWI705975B (zh) 2017-04-20 2018-04-09 抗－N3pGlu類澱粉β肽抗體及其用途

Country Status (28)

Country Link
US (3) US10647759B2 (enExample)
EP (1) EP3612559A1 (enExample)
JP (3) JP6900500B2 (enExample)
KR (2) KR102352670B1 (enExample)
CN (2) CN117024583A (enExample)
AR (1) AR111208A1 (enExample)
AU (2) AU2018255221B2 (enExample)
BR (1) BR112019018810A2 (enExample)
CA (1) CA3058482C (enExample)
CL (1) CL2019002922A1 (enExample)
CO (1) CO2019011349A2 (enExample)
CR (1) CR20190445A (enExample)
DO (1) DOP2019000241A (enExample)
EA (1) EA201992163A1 (enExample)
EC (1) ECSP19075146A (enExample)
IL (1) IL269003B2 (enExample)
JO (1) JOP20190247A1 (enExample)
MA (1) MA50144A (enExample)
MX (2) MX2019012445A (enExample)
NZ (1) NZ758066A (enExample)
PE (1) PE20200011A1 (enExample)
PH (1) PH12019502361A1 (enExample)
SA (1) SA519410311B1 (enExample)
SG (1) SG11201909022PA (enExample)
TW (2) TWI789644B (enExample)
UA (1) UA126806C2 (enExample)
WO (1) WO2018194951A1 (enExample)
ZA (1) ZA202007868B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
PE20212266A1 (es) 2019-03-26 2021-11-30 Janssen Pharmaceutica Nv ANTICUERPOS CONTRA AMILOIDE-ß CON PIROGLUTAMATO Y USOS DE ESTOS
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
MX2023003836A (es) 2020-10-02 2023-04-14 Lilly Co Eli Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas.
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
WO2023070064A1 (en) * 2021-10-22 2023-04-27 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
MX2024005153A (es) * 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a la interleucina-34.
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
US20250296997A1 (en) 2021-10-29 2025-09-25 Eli Lilly And Company Compounds and methods targeting interleukin-34
CA3236560A1 (en) * 2021-10-29 2023-05-04 Marcio Chedid Compounds and methods targeting interleukin-34
US20250064417A1 (en) 2022-02-03 2025-02-27 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
EP4619103A1 (en) * 2022-11-17 2025-09-24 Eli Lilly and Company Anti-n3pglu amyloid beta antibodies, doses, and uses thereof
IL321331A (en) 2022-12-22 2025-08-01 Bioarctic Ab Antibody that binds to ABETAPE3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142806A1 (en) * 2010-08-12 2013-06-06 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1257584T2 (sl) * 2000-02-24 2013-07-31 Washington University St. Louis Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CA2723995A1 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
EP3338796A1 (en) 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
TWI703159B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142806A1 (en) * 2010-08-12 2013-06-06 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
US20140065138A1 (en) * 2010-08-12 2014-03-06 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
BR112019018810A2 (pt) 2020-05-05
UA126806C2 (uk) 2023-02-08
MX2022011817A (es) 2022-10-10
AR111208A1 (es) 2019-06-12
AU2018255221A1 (en) 2019-09-19
US20210371509A1 (en) 2021-12-02
CN110582511B (zh) 2023-08-08
CR20190445A (es) 2019-11-06
TW201902924A (zh) 2019-01-16
TWI705975B (zh) 2020-10-01
KR20190129100A (ko) 2019-11-19
TW202120541A (zh) 2021-06-01
US10647759B2 (en) 2020-05-12
IL269003B1 (en) 2025-06-01
US20200262902A1 (en) 2020-08-20
KR20220011800A (ko) 2022-01-28
KR102567295B1 (ko) 2023-08-16
ZA202007868B (en) 2023-06-28
CA3058482A1 (en) 2018-10-25
JP7227312B2 (ja) 2023-02-21
JP7532571B2 (ja) 2024-08-13
CA3058482C (en) 2023-05-09
PH12019502361A1 (en) 2020-07-13
AU2021203927A1 (en) 2021-07-08
US11078261B2 (en) 2021-08-03
IL269003A (en) 2019-10-31
MA50144A (fr) 2020-07-29
WO2018194951A1 (en) 2018-10-25
EP3612559A1 (en) 2020-02-26
JP2021151253A (ja) 2021-09-30
JP6900500B2 (ja) 2021-07-07
SA519410311B1 (ar) 2022-03-20
AU2021203927B2 (en) 2024-03-21
US20180305444A1 (en) 2018-10-25
ECSP19075146A (es) 2019-10-31
DOP2019000241A (es) 2019-10-15
SG11201909022PA (en) 2019-11-28
CO2019011349A2 (es) 2019-10-31
JP2023058623A (ja) 2023-04-25
CN117024583A (zh) 2023-11-10
MX2019012445A (es) 2020-01-13
PE20200011A1 (es) 2020-01-06
JP2020510081A (ja) 2020-04-02
KR102352670B1 (ko) 2022-01-19
CN110582511A (zh) 2019-12-17
CL2019002922A1 (es) 2020-03-13
EA201992163A1 (ru) 2020-03-02
JOP20190247A1 (ar) 2019-10-20
NZ758066A (en) 2022-10-28
IL269003B2 (en) 2025-10-01
AU2018255221B2 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
JP7532571B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
CA3007000C (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
US10988529B2 (en) Combination therapy
EA048806B1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение
BR122024022779A2 (pt) Molécula de ácido nucleico, célula de mamífero, processo para produzir um anticorpo anti-n3pg ab